

Identifying “red flags” when re-assessing screening programmes.

On behalf of the screening re-assessment collaborating group:

Karsten Juhl Jørgensen
Deputy Director, MD, DrMedSci
The Nordic Cochrane Centre



The screening re-assessment collaborating group

Project leads:

1. **Fabienne Ropers**
2. **Christiana Naaktgeboren**
3. **Karsten Juhl Jørgensen**
4. **Wynne Norton**

Affiliation:

- Leiden University Medical Center, Netherlands**
University Medical Center Utrecht, Netherlands
Nordic Cochrane Centre, Denmark
National Cancer Institute, USA

Members

- | | |
|------------------------|---|
| 1. Alexandra Barratt | University of Sydney, Australia |
| 2. Erica Breslau | National Cancer Institute, USA |
| 3. John Brodersen | University of Copenhagen, Denmark |
| 4. Stacey Carter | University of Sydney, Australia |
| 5. Laura Esserman | University of California San Francisco, USA |
| 6. Lorna Gibson | University of Edinburgh, Scotland |
| 7. Paul Glaziou | Bond University, Australia |
| 8. Laragh Gollogly | WHO, Switzerland |
| 9. Russell Harris | University of North Carolina, USA |
| 10. Jolyn Hersch | University of Sydney, Australia |
| 11. Pauline Heus | University Medical Center Utrecht, Netherlands |
| 12. Lotty Hooft | Cochrane Netherlands |
| 13. Gemma Jacklyn | University of Sydney, Australia |
| 14. Minna Johansson | University of Gothenburg, Sweden |
| 15. Pamela Marcus | National Cancer Institute, USA |
| 16. Kirsten McCafferey | University of Sydney, Australia |
| 17. Stuart Nicholls | University of Ottawa, Canada |
| 18. Susan Norris | WHO, Switzerland |
| 19. Jack O'Sullivan | University of Oxford, UK |
| 20. Lisa Schwartz | The Dartmouth Institute, USA |
| 21. Yiwey Shieh | University of San Francisco, USA |
| 22. Rachel Thompson | The Dartmouth Institute, USA |
| 23. Yu Wang | Peking University Health Science Center |
| 24. Jane Williams | University of Sydney, Australia |
| 25. Timothy Wilt | University of Minnesota School of Medicine, USA |
| 26. Steven Woloshin | The Dartmouth Institute, USA |



PUBLIC HEALTH PAPERS

34

PRINCIPLES AND PRACTICE
OF SCREENING FOR
DISEASE

J. M. G. WILSON & G. JUNGNER



WORLD HEALTH ORGANIZATION
GENEVA



Nordic Cochrane Centre

Project outline

- Explain the need for and outline a framework for re-assessment of current screening practises.
- ***3 components.***
- 1: Standardising re-assessment procedures.
- **2: Identifying “red flags” for re-assessment.**
- 3: Guidance on practical de-intensification or de-implication and monitoring its effects.



Component 2: Identifying “red flags”

- Mark critical warning signs of lack of net benefit.
- Identifies these “red flags” based on a review of historical examples of screening interventions that have been de-intensified or de-implemented.
- These flags will be classified according to the PICO-format.



Review of examples

- Two authors independently and systematically reviewed recommendations on screening from key institutions. These were supplemented with discussions within the whole group.
- US Preventive Services Task Force, the Canadian Task Force, Choosing Wisely, and NHS screening recommendations.
- We identified 22 types of screening with recommendations of restricted use compared to previous practise; where screening was recommended against; or a strong rationale for this has been made.
- **P**: Change within population: tuberculosis diminishes.
- **I**: New screening strategy: strong evidence that once-only sigmoidoscopy is superior to FOBT.
- **C**: New effective standard treatment or prevention strategy: HPV-vaccine.
- **O**: Substantial overdiagnosis accepted: prostate cancer screening.



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	
Harmless examination	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	
Harmless examination	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	
Harmless examination	
Specific target group	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	
Harmless examination	
Specific target group	
Once only test	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	
Harmless examination	
Specific target group	
Once only test	
No invasive follow-up tests	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	ARR: 0,46% (46/10,000) (But likely -77% today)
Harmless examination	
Specific target group	
Once only test	
No invasive follow-up tests	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	ARR: 0,46% (46/10,000) (But likely -77% today)
Harmless examination	Overdiagnosis: 176 / 10,000
Specific target group	
Once only test	
No invasive follow-up tests	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	ARR: 0,46% (46/10,000) (But likely -77% today)
Harmless examination	Overdiagnosis: 176 / 10,000
Specific target group	Overtreatment: 37 / 10,000
Once only test	
No invasive follow-up tests	



Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.

GOOD!	BAD!
RRR: 50%	ARR: 0,46% (46/10,000) (But likely -77% today)
Harmless examination	Overdiagnosis: 176 / 10,000
Specific target group	Overtreatment: 37 / 10,000
Once only test	Deaths from OT: 2 / 10,000
No invasive follow-up tests	




Screening for abdominal aortic aneurysm

Evidence: 4 RCT's, 137,214 men over 65 years, > 10 years of FU. Performed during 1980's and 1990's.


GOOD!	BAD!
RRR: 50%	ARR: 0,46% (46/10,000) (But likely -77% today)
Harmless examination	Overdiagnosis: 176 / 10,000
Specific target group	Overtreatment: 37 / 10,000
Once only test	Deaths from OT: 2 / 10,000
No invasive follow-up tests	Further compl.: 12/10,000



Figure 1. The value framework.



Archie Cochrane's challenge



“It is surely a great criticism of our profession that we have not organised a critical summary, by specialty or subspecialty, adapted periodically, of all relevant randomised controlled trials.”

Cochrane 1979



Challenge from the screening re-assessment collaborating group:

“It is surely a great criticism of our profession that we have not organised an independent critical review process, adapted periodically, and following a structured, empirically founded methodology, of the evidence base for all currently used screening interventions”.

